483 Roundup: FDA Cites Eight Firms for Quality Issues Post author:Sam Post published:May 5, 2020 Post category:Drug GMP Report The FDA found a range of quality lapses during inspections at eight U.S.-based plants. Source: Drug GMP Report You Might Also Like Proposed Senate Bill Would Give FDA Drug Recall Authority September 10, 2020 California Compounder Draws Warning for Repeated Violations July 6, 2020 FDA Issues 483 to Novo Nordisk for Inadequate Sterility Controls March 8, 2016